Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of radiotherapy plus dihydroartemisinin for breast cancer brain metastases
ChiCTR2500103939Phase 2Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dihydroartemisinin in breast cancer and brain metastases, sponsored by Yunnan Cancer Hospital. Primary endpoints: Intracranial control rate at 6 months, Intracranial control rate at 1 year and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
dihydroartemisinin
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2500103939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103939.